BIIB SEC Filing News — Biogen Inc.

Latest SEC filings for Biogen Inc. (BIIB) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-29.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc…
Sector: Healthcare Industry: Drug Manufacturers - General Market Cap: $30.0B CIK: 875045
20
Total Filings
0
Bullish Signals
0
Bearish Signals
11
Insider Transactions
7
Material Events (8-K)
2
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Biogen Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
BIIB Filing Activity Snapshot 2026-04-03 — 2026-07-29
Insider Transactions (Form 4)
0 buys vs 0 sells
Insider buying and selling activity is balanced in this period.
Recent SEC Filings
Form 10-Q Quarterly Report 2026-07-29

BIIB filed Quarterly Report (10-Q)

BIOGEN INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-29

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-01

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

HAWKINS WILLIAM A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: HAWKINS WILLIAM A (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

SHERWIN STEPHEN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: SHERWIN STEPHEN A (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Rowinsky Eric K (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Rowinsky Eric K (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Mantas Jesus B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Mantas Jesus B (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

LANGER SUSAN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: LANGER SUSAN (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Patolawala Monish D (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Patolawala Monish D (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Pangalos Menelas N (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Pangalos Menelas N (Director) Shares: 3,875
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Minor Lloyd (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Minor Lloyd (Director) Shares: 1,505
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-06-11

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Freire Maria C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Freire Maria C (Director) Shares: 2,005
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-10

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K/A Amended Material Company Update 2026-06-10

BIIB filed amended 8-K — material company event

BIOGEN INC. filed an amended 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K/A (Material Event Amendment)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-14

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-05-05

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Keeney Adam (Head of Corporate Development) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Keeney Adam (Head of Corporate Development) Shares: 1,394
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-04-29

BIIB filed Quarterly Report (10-Q)

BIOGEN INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-29

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-06

BIIB filed 8-K — material company event

BIOGEN INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Tax / Compensation Filing 2026-04-03

BIIB insider Form 4 filed for equity award, exercise, or tax withholding

Godbout Sean (Chief Accounting Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Filing: Form 4 (Insider Transaction) Insider: Godbout Sean (Chief Accounting Officer) Shares: 235
View on SEC EDGAR → Open Filing Document →

Understanding Biogen Inc.'s SEC Filings

Form 4 — Insider Transactions

Executives, directors, and large shareholders must report any purchase or sale of BIIB shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.

Form 144 — Proposed Insider Sales

Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.

8-K — Material Events

The 8-K is an event-driven filing that Biogen Inc. must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.

10-Q & 10-K — Periodic Reports

The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Biogen Inc.'s financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.

Frequently Asked Questions — BIIB SEC Filings

What SEC filings does Biogen Inc. submit to the SEC?

Biogen Inc. (BIIB) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BIIB?

A Form 4 for BIIB discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the date, number of shares bought or sold, the price, and the insider's updated total ownership. Consistent insider buying across multiple executives is often interpreted as a bullish signal.

How do I interpret an 8-K filing from Biogen Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BIIB?

The 10-K is Biogen Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BIIB SEC filings directly on EDGAR?

You can view all historical Biogen Inc. filings on the SEC EDGAR company page for BIIB. Each filing card on this page links directly to the original SEC document.

How often does Biogen Inc. file with the SEC?

Biogen Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BIIB shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for BIIB

BIIB Full Stock Analysis BIIB Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Demand Zone Analyzer Sector Scanner Browse All Stocks

Want deeper BIIB analysis?

View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the BIIB stock analysis page.

BIIB Full Analysis
SEC filing data is sourced from SEC EDGAR. This page is updated automatically as new filings are detected. Content is for informational purposes only and does not constitute investment advice. Full Disclaimer.